Cladribine as a therapeutic option in multiple sclerosis

被引：10
|
作者：
Warnke, Clemens [1 ]
Leussink, Verena I. [1 ]
Goebels, Norbert [1 ]
Aktas, Orhan [1 ]
Boyko, Alexey [2 ,3 ]
Kieseier, Bernd C. [1 ]
Hartung, Hans-Peter [1 ]
机构：
[1] Univ Dusseldorf, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany
[2] Russian State Med Univ, Dept Neurol & Neurosurg, Moscow 117437, Russia
[3] Moscow MS Ctr, Moscow, Russia
来源：
CLINICAL IMMUNOLOGY | 2012年 / 142卷 / 01期
关键词：
Cladribine; Multiple sclerosis; Immunosuppressant; Oral drugs; DOUBLE-BLIND; 2-CHLORODEOXYADENOSINE; TOXICITY; 2-CHLORO-2'-DEOXYADENOSINE; APOPTOSIS; TABLETS; SAFETY; CELLS; TRIAL;
D O I：
10.1016/j.clim.2011.05.009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug. (C) 2011 Published by Elsevier Inc.
引用
收藏
页码：68 / 75
页数：8
相关论文
共 50 条
  • [31] Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
    Radojka M. Savic
    Ana M. Novakovic
    Marianne Ekblom
    Alain Munafo
    Mats O. Karlsson
    Clinical Pharmacokinetics, 2017, 56 : 1245 - 1253
  • [32] Cladribine personalised dosing to treat multiple sclerosis
    Mao, Z.
    Alvarez-Gonzalez, C.
    Allen-Philbey, K.
    Turner, B.
    Gnanapavan, S.
    Marta, M.
    Mathews, J.
    Giovannoni, G.
    Baker, D.
    Schmierer, K.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 609 - 609
  • [33] Cladribine - A review of its use in multiple sclerosis
    Langtry, HD
    Lamb, HM
    BIODRUGS, 1998, 9 (05) : 419 - 433
  • [34] Cladribine to Treat Relapsing Forms of Multiple Sclerosis
    Gavin Giovannoni
    Neurotherapeutics, 2017, 14 : 874 - 887
  • [35] The treatment of chronic progressive multiple sclerosis with cladribine
    Beutler, E
    Sipe, JC
    Romine, JS
    Koziol, JA
    McMillan, R
    Zyroff, J
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) : 1716 - 1720
  • [36] Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine
    Biernacki, Tamas
    Sandi, Daniel
    Bencsik, Krisztina
    Vecsei, Laszlo
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2020, 20 (04) : 269 - 285
  • [37] Development of oral cladribine for the treatment of multiple sclerosis
    Hans-Peter Hartung
    Orhan Aktas
    Bernd Kieseier
    Giancarlo Comi
    Journal of Neurology, 2010, 257 : 163 - 170
  • [38] PERSONALISED DOSING OF CLADRIBINE TO TREAT MULTIPLE SCLEROSIS
    Mao, Zhifeng
    Alvarez-Gonzalez, Cesar
    Allen-Philbey, Kimberley
    Mathews, Joela
    Turner, Benjamin P.
    Gnanapavan, Sharmilee
    Marta, Monica
    Baker, David
    Giovannoni, Gavin
    Schmierer, Klaus
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A47 - A48
  • [39] Clinical practice experience with cladribine in multiple sclerosis
    Meca-Lallana, V.
    Aguirre, C.
    Torres, J.
    Diaz, C.
    Del Rio, B.
    Martin, R.
    Vivancos, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 138 - 139
  • [40] Personalised dosing of cladribine for people with multiple sclerosis
    Mao, Zhifeng
    Alvarez-Gonzalez, Cesar
    Yildiz, Ozlem
    Allen-Philbey, Kimberley
    Turner, Benjamin
    Gnananpavan, Sharmilee
    Marta, Monica
    Mathews, Joela
    Giovannoni, Gavin
    Baker, David
    Schmierer, Klaus
    NEUROLOGY, 2018, 90
12345